GeneDx Faces Securities Class Action Lawsuit Over Fabric Acquisition

The legal complaint contends that GeneDx executives consistently touted the Fabric acquisition as a catalyst for improved financial performance and cost-of-goods-sold reductions. Specifically, the company claimed it could optimize dry lab processes by merging capabilities. However, plaintiffs argue that these representations were false or reckless, as the company allegedly ignored significant structural problems within Fabric that undermined its business operations.

Shareholders who suffered losses during this period have until August 3, 2026, to seek appointment as lead plaintiff. While registration allows investors to participate in potential recoveries and access portfolio monitoring services, it carries no upfront cost or obligation. Interested parties may contact The Gross Law Firm in New York to submit their claims and receive status updates as the litigation proceeds.